Abstract
Disparities between blacks and whites with respect to comorbidities, health outcomes and access to care have all been well documented. Black populations have higher prevalence of risk factors for cardiovascular disease, specifically hypertension and diabetes, and bear a disproportionate burden of cardiovascular disease [1, 2]. Differences in the incidence of disease and disease outcomes also exist in the arena of oncology where blacks continue to have worse outcomes with the highest death rates and lowest survival from most cancers of any racial or ethnic group [3,4,5]. Given that hypertension, diabetes and cardiovascular disease all increase the risk of cardiac complications from many forms of oncologic care, the question of whether this population also experiences disparate rates of cardiac complications from oncologic care and whether any such differences could contribute to the gap in cancer outcomes requires investigation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;111(10):1233–41. https://doi.org/10.1161/01.CIR.0000158136.76824.04 PMID: 15769763.
Safford MM, Brown TM, Muntner PM, Durant RW, Glasser S, Halanych JH, et al. REGARDS Investigators. Association of race and sex with risk of incident acute coronary heart disease events. JAMA. 2012;308(17):1768–74. https://doi.org/10.1001/jama.2012.14306. PMID: 23117777; PMCID: PMC3772637.
Aizer AA, Wilhite TJ, Chen MH, Graham PL, Choueiri TK, Hoffman KE, et al. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer. 2014;120(10):1532–9. https://doi.org/10.1002/cncr.28617 Epub 2014 Feb 22 PMID: 24863392.
DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69(3):211–33. https://doi.org/10.3322/caac.21555 Epub 2019 Feb 14 PMID: 30762872.
Ward EM, Sherman RL, Henley SJ, Jemal A, Siegel DA, Feuer EJ, et al. Annual report to the nation on the status of cancer, featuring cancer in men and women age 20–49 years. J Natl Cancer Inst. 2019;111(12):1279–97. https://doi.org/10.1093/jnci/djz106. PMID: 31145458; PMCID: PMC6910179.
Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15(4):1544–52. https://doi.org/10.1200/JCO.1997.15.4.1544 PMID: 9193351.
Hasan S, Dinh K, Lombardo F, Kark J. Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc. 2004;96(2):196–9. PMID: 14977278; PMCID: PMC2594938.
Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D’Ascenzo F, Malavasi V, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112(12):1980–4. https://doi.org/10.1016/j.amjcard.2013.08.026 Epub 2013 Sep 25 PMID: 24075281.
Scully RE, Lipshultz SE. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol. 2007;7(2):122–8.
Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8. https://doi.org/10.1161/CIRCULATIONAHA.114.013777 Epub 2015 May 6 PMID: 25948538.
Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, et al. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 2018;8(7):67. https://doi.org/10.1038/s41408-018-0102-7. PMID: 29980678; PMCID: PMC6035273
Ailawadhi S, Advani P, Yang D, Ghosh R, Swaika A, Roy V, et al. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: a SEER registry analysis. Cancer. 2016;122(4):618–25. https://doi.org/10.1002/cncr.29771 Epub 2015 Nov 13 PMID: 26565660.
West DW, Satariano WA, Ragland DR, Hiatt RA. Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol. 1996;6(5):413–9. https://doi.org/10.1016/s1047-2797(96)00096-8 PMID: 8915472.
Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005;294(14):1765–72. https://doi.org/10.1001/jama.294.14.1765 PMID: 16219879.
Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019;133(24):2615–8. https://doi.org/10.1182/blood.2019000406. Epub 2019 Apr 19. PMID: 31003998; PMCID: PMC6566591.
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–6. https://doi.org/10.1001/jama.291.22.2720. PMID: 15187053.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
29.1 Electronic supplementary material
Below is the link to the electronic supplementary material.
Video 29.1
Transthoracic echocardiogram (TEE) two and four chamber views showing severely reduced LV function with an ejection fraction of 17% (PPTX 5969 kb)
Video 29.2
TEE two and four chamber views showing mildly reduced EF (EF 50%), concentric LVH (PPTX 3481 kb)
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Johnson, M.N. (2021). Health Care Disparities in Cardio-Oncology. In: Steingart, R.M., Liu, J.E. (eds) Atlas of Imaging in Cardio-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-70998-3_29
Download citation
DOI: https://doi.org/10.1007/978-3-030-70998-3_29
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-70997-6
Online ISBN: 978-3-030-70998-3
eBook Packages: MedicineMedicine (R0)